11-15-2009

Determination of 6-benzylthioinosine in Mouse and Human Plasma by Liquid Chromatography–Tandem Mass Spectrometry

Lan Li

Cleveland State University

Yan Xu

Cleveland State University, y.xu@csuohio.edu

David N. Wald

Case Western Reserve University

William Tse

Case Western Reserve University

Follow this and additional works at: https://engagedscholarship.csuohio.edu/scichem_facpub

Part of the [Analytical Chemistry Commons](#)

[How does access to this work benefit you? Let us know!](#)

Recommended Citation

Li, Lan; Xu, Yan; Wald, David N.; and Tse, William, "Determination of 6-benzylthioinosine in Mouse and Human Plasma by Liquid Chromatography–Tandem Mass Spectrometry" (2009). *Chemistry Faculty Publications*. 175.

https://engagedscholarship.csuohio.edu/scichem_facpub/175

This Article is brought to you for free and open access by the Chemistry Department at EngagedScholarship@CSU. It has been accepted for inclusion in Chemistry Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.

Determination of 6-benzylthioinosine in mouse and human plasma by liquid chromatography–tandem mass spectrometry

Lan Li , Yan Xu , David N. Wald , William Tse

Introduction

6-Benzylthioinosine (6BT) is an adenosine analogue (Fig. 1) and was originally used in the property studies of adenosine aminohydrolase [1]. In the later 1990s, 6BT was found to be potentially useful in the treatment of toxoplasmosis [2,3] caused by *Toxoplasma gondii*, an intracellular parasite that infects humans and many other warm-blooded animals [4,5]. Recently, 6BT was identified as a promising differentiation-inducing agent for leukemic cells as less toxic and more efficacious treatment for acute myeloid leukemia (AML) [6].

According to statistics by American Society of Clinical Oncology in 2008, AML is the most common form of acute leukemia in the United States and is most often observed in elderly population over age 65 [7,8]. The molecular pathogenesis of AML is generally accepted as a combination of differentiation arrest and the uncontrolled proliferation of the myeloblasts [9]. The stan-

dard chemotherapy agents such as adriamycin and cytarabine work through nonselectively killing highly proliferative cells leading to significant toxicities [8]. Although up to 75% of the patients can achieve complete remission (CR), the prognosis of the patients remains poor leading to an average 5-year survival rate as low as 21% [7]. In contrast to the traditional chemotherapeutics that are used for the majority of AML patients, the treatment of acute promyelocytic leukemia (APL, a rare subtype of AML), utilizes a differentiation-inducing agent, all-trans retinoic acid (ATRA), that increases the 5-year disease free survival rate of the patients to 74% through inducing the terminal differentiation of the myeloblasts [10]. ATRA can be effectively used in combination with low dose chemotherapeutic agents without significant toxicity [11]. This differentiation approach is especially desirable for elderly patients who are often not able to tolerate the toxicities of the traditional chemotherapeutics.

Since ATRA is only useful for AML patients exhibiting the rare APL subtype, to search for efficacious differentiation-inducing agents for the treatment of other AML subtypes, Wald et al. [6] carried out a cell-based compound-library screen. 6BT has been identified as a promising differentiation-inducing agent that not only displays high differentiation-inducing activity to myeloid leukemia cell lines (i.e., HL-60 and OCI-AML3) and primary cells

Fig. 1. The chemical structures of 6BT and the internal standard.

of AML patients, but also induces cell death to a subset of AML cell lines (*i.e.*, HNT34 and MV4-11). Furthermore, 6BT exhibits very low toxicity to non-malignant cells (*i.e.*, fibroblasts, normal bone marrow, and endothelial cells). In mouse xenograft studies, 6BT significantly decreased the tumor (HL-60) size and prevented tumor (HL-60 and MV4-11) formation in pretreated mice. Flow cytometric analysis of the dissected tumors showed a 129% increase of CD11b (a mature myeloid marker) in 6BT treated tumors in comparison to the untreated ones [6].

The preclinical studies of 6BT for the treatment of AML and toxoplasmosis demonstrated its high potential to be an investigational new drug and warrants further therapeutic development. Therefore, a quantitative analytical method for 6BT is needed for pharmacological and toxicological studies. Nevertheless, a recent search by SciFinder® Scholar revealed that there is no analytical method available to date for quantification of 6BT in biological matrices. Only a qualitative LC–UV method for 6BT and its analogues was reported by Rais *et al.* [12], which was not validated for quantitative measurement of 6BT and did not have the sensitivity and specificity required for pharmacokinetic study of 6BT.

Given the above considerations, we have developed a novel LC–MS/MS method for the direct quantification of 6BT in both mouse and human plasma using 2-amino-6-benzylthioinosine (2A6BT) (Fig. 1) as the internal standard (IS). A liquid–liquid extraction procedure was developed for plasma sample preparation, and analytes were separated by YMC ODS-AQ® column using 0.1% formic acid, 45% acetonitrile and 54.9% deionized water (*v/v/v*) as mobile phase. The eluates from the chromatographic column were detected by tandem mass spectrometer at the positive ionization mode (ESI⁺-MS/MS). The method developed fills the gap of lacking analytical method for quantitative measurement of 6BT, which has been validated in both mouse and human plasma according to the US Food and Drug Administration (FDA) guidelines [13], and applied to a preliminary pharmacokinetic study of 6BT in mice.

Experimental

Chemicals and solutions

6BT and 2A6BT (IS) were kindly provided by the Developmental Therapeutics Program of the National Cancer Institute (Bethesda, MD, USA). Dimethylsulfoxide (DMSO), HPLC-grade of acetonitrile and ethyl acetate were purchased from Sigma–Aldrich (St. Louis, MO, USA). Formic acid was from Acros (Morris Plains, NJ, USA). Deionized water was obtained from the Barnstead NANOpure® water purification system (Thermo Scientific, Waltham, MA, USA). Pooled blank mouse plasma was purchased from Equitech-Bio (Kerrville, TX, USA). Pooled blank human plasma was from Haemtech, Inc. (Essex Junction, VT, USA). Isoflurane was purchased from Baxter Healthcare Corporation (Deerfield, IL, USA).

6BT and IS stock solutions were prepared and kept as follows: each compound was weighted out accurately by an analytical balance and dissolved into an appropriate amount of acetonitrile to a concentration of 1.00 mg/mL; then, each stock solution was pipetted separately into 1.5-mL microcentrifuge tubes at 100 μ L/tube for 6BT and 25.0 μ L/tube for IS. The microcentrifuge tubes containing either 6BT (100 μ g/tube) or IS (25.0 μ g/tube) stock solution were dried by vacuum evaporation in a DNA120 SpeedVac® (ThermoSavant, Hollbrook, NY, USA) at 25 °C for 10 min, and kept at –20 °C until use. When used, 1.00 mL of deionized water was added to each tube to make 6BT and IS working solutions at 100 and 25.0 μ g/mL, respectively. The working solutions of 6BT and IS were freshly prepared daily.

The mobile phase for chromatographic separation was prepared by mixing 0.1% formic acid, 45.0% acetonitrile and 54.9% deionized water (*v/v/v*).

Instrumentation

The LC–MS/MS system consisted of an Agilent (Santa Clara, CA, USA) 1100 HPLC and a Micromass (Manchester, UK) Quattro II triple quadrupole mass spectrometer. The HPLC unit consisted of two binary pumps, a degasser, an autosampler, an inline filter (0.5 μ m pore) (Upchurch Scientific, Oak Harbor, WA, USA), a Waters (Milford, MA, USA) YMC-AQ® column (2.0 mm $\times$ 50 mm, 5 μ m particle size with 120 Å pore size), a two-position 6-port switching valve (Alltech, Deerfield, IL, USA), and a post-column splitter (Valco, Houston, TX, USA). The LC–MS/MS system operation, data acquisition and processing were done by Micromass MassLynx software (version 3.3).

For each analysis, 20 μ L of the sample was injected into the system. Chromatographic separation was carried out by isocratic elution using the mobile phase at the flow rate of 100 μ L/min. By programming of the post-column switching valve, the first 2-min column eluate was diverted to the waste and the later eluate was detected by the triple quadrupole mass spectrometer after a post-column split (1:3).

The mass spectrometer was operated at the positive-electrospray-ionization (ESI⁺) mode. It was tuned by infusion of a mixture of 6BT (10.0 μ g/mL) and IS (10.0 μ g/mL) in the mobile phase at a flow rate of 3 μ L/min with a syringe pump (Harvard Apparatus, South Natick, MA, USA). The optimized ionization conditions were as follows: drying gas 300 L/h, nebuliser 15 L/h, capillary voltage 3.5 kV, HV lens 0.5 kV, cone voltage 25 V, skimmer 1.5 V, RF lens 0.2 V, ion source temperature 40 °C, ion energy 0.3 V. Analyte quantification was based on multiple-reaction-monitoring (MRM) with the conditions set as follows: argon collision gas 2.0–2.5 μ bar, collision energy 17 eV, dwell time 0.4 s, inter-scan delay 0.05 s, low- and high-mass resolution 15 (for both quadrupoles 1 and 3), and multiplier 650.

Preparation of standard solutions, plasma calibrators and controls, and mouse plasma samples

6BT standard solutions (6.00, 18.0, 20.0, 60.0, 180, 200, 600, 1800, 2000, and 3200 ng/mL) and IS standard solution (100 ng/mL) were prepared by serial dilution of 6BT working solution (100 µg/mL) and IS working solution (25.0 µg/mL), respectively.

6BT mouse and human plasma calibrators (3.00, 10.0, 30.0, 100, 300, and 1000 ng/mL) were prepared individually by mixing 100 µL of pooled blank plasma, 50.0 µL of 6BT standard solution (at twice of the calibrator's concentration) and 50 µL of IS standard solution at 100 ng/mL.

6BT mouse plasma controls (3.00, 9.00, 90.0, 900, and 1600 ng/mL) and 6BT human plasma controls (3.00, 90.0 and 900 ng/mL) were prepared individually by mixing 100 µL of pooled blank plasma, 50.0 µL of 6BT standard solution (at twice of the control's concentration) and 50 µL of IS standard solution at 100 ng/mL.

Mouse plasma samples of 6BT pharmacokinetic study (see Section 2.6) were prepared by mixing 100 µL of plasma from mice injected with 6BT, 50.0 µL of deionized water and 50.0 µL of IS standard solution at 100 ng/mL.

Liquid-liquid extraction of 6BT from plasma matrices

Plasma calibrators, controls and animal samples prepared as described in Section 2.3 were extracted using the following protocol: 1 mL of ethyl acetate was added into a 1.5 mL microcentrifuge tube containing plasma sample. After vortexing for 1 min, the mixture was centrifuged at $13,000 \times g$ for 10 min. Then, 850 µL of the organic phase (ca. 85% of the upper layer) was transferred into a clean 1.5-mL microcentrifuge tube and placed in a DNA 120 SpeedVac® (ThermoSavant, Hollbrook, NY, USA). The organic phase containing 6BT and IS was vacuumed to dryness at 25 °C for 30 min. The sample residue was reconstituted in 85 µL of water before analysis.

Matrix effect and recovery

For the matrix effect study, aliquots of 100-µL pooled blank plasma together with 100 µL of water were first extracted using the protocol described in Section 2.4. Then, 6BT and IS standard solutions were spiked in the extracted plasma matrix resulting in 6BT concentrations of 9.00, 90.0 and 900 ng/mL and an IS concentration of 50.0 ng/mL. The peak area ratios of 6BT to IS in these spike-after-extraction (SAE) standards were compared with those of the corresponding aqueous standard solutions.

For the recovery study, 6BT plasma calibrators at concentrations of 9.00, 90.0 and 900 ng/mL with an IS concentration of 50.0 ng/mL were analyzed. The peak area ratios of 6BT to IS in the plasma calibrators were compared with those of the corresponding SAE standards for calculation of IS normalized recovery of 6BT. The peak areas of IS in the plasma calibrators were compared with those of the corresponding SAE standards for the calculation of absolute recovery of the IS.

Stability

Mouse and human plasma test controls (9.00 and 900 ng/mL) were prepared as described in Section 2.3 except the IS standard was added prior to the liquid-liquid extraction. All experiments were run in triplicate and the results were compared with freshly prepared plasma controls.

For the freeze and thaw stability study, the test controls were undergone three freeze and thaw cycles. In each cycle, the test controls were frozen for at least 24 h at -20°C and thawed at room

temperature without help. The short-term temperature stability study was carried out by leaving the test controls at the room temperature (23°C) for 4–24 h. For the long-term stability, the test controls were stored at -20°C for 30 days prior to analysis.

Method application

The feasibility of the method developed was tested by a preliminary pharmacokinetics study of 6BT in mice. Pharmacokinetic parameters of 6BT were determined using male C57BL/6 mice from Charles River Laboratories International (Spencerville, OH, USA). The mice were randomly housed in a group of five, with an average body weight of 24 g at the time of treatment. 6BT injection solution (0.2 mg/mL) was prepared in 10% DMSO–PBS (1×) solution and given intraperitoneally as single bolus injection at a dose of 1 mg/kg.

Mouse blood samples were collected into 1.5-mL centrifuge tubes by cardiac puncture using heparinized needle and syringe under isoflurane anesthesia at 5, 13, 22, 35, 45, 58, 121 and 237 min post-6BT injection. An average of 0.4 mL of blood sample was collected from each mouse. The whole blood was placed on ice immediately and centrifuged at $8000 \times g$ for 15 min within 1 h of the collections. The harvested plasma samples were frozen at -20°C until analysis. Mouse plasma from mouse injected with 10% DMSO–PBS (1×) was used as the predose plasma sample.

Pharmacokinetic analysis was done by WinNonLin nonlinear estimation program (Version 5.2) (Pharsight Corp., Mountain View, CA, USA) using PK model 5 (1 compartment 1st order, $K_{10} = K_{01}$, 1st order elimination).

Results and discussion

Method development

Mass spectrometric detection

In this work, the optimization of 6BT and 2A6BT (IS) responses was done using the “auto-tune” function of the MassLynx. Since 6BT and the IS were more easily to form protonated species than deprotonated species by electrospray ionization, the positive-electrospray-ionization mode was used for 6BT identification and quantification. As shown in Fig. 2A and B (the m/z scan by the first quadrupole), 6BT and the IS produced predominant molecular ions at m/z 375 for $[6\text{BT}+\text{H}]^{+}$ and m/z 390 for $[\text{IS}+\text{H}]^{+}$, respectively. These molecular ions produced were further dissociated into product ions by collision with argon gas in the second quadrupole (Fig. 2C and D). The predominant product ions of $[6\text{BT}+\text{H}]^{+}$ and $[\text{IS}+\text{H}]^{+}$ were m/z 243 and m/z 258, respectively. Therefore, the mass transition pairs m/z 375 > 243 and m/z 390 > 258 for 6BT and the IS were chosen for quantification by multiple-reaction-monitoring (MRM) mode.

The major fragments of 6BT and the IS were proposed by comparing the chemical structures of these compounds together with the m/z differences between the predominant product ions and shown in Fig. 3.

Chromatographic separation

Since the $\log D$ values of 6BT and 2A6BT at pH 3 (*i.e.*, pH of the mobile phase) are 1.45 and 0.94 as given by SciFinder®, these analytes are rather hydrophobic than hydrophilic. Therefore, reverse-phase LC column was used for analytical separation. In this work, two C18-based columns, Phenomenex Gemini® column (2.0 mm $\times$ 50 mm, 5 µm particle size with 110 Å pore size) and Waters YMC ODS-AQ® column (2.0 mm $\times$ 50 mm, 5 µm particle size with 120 Å pore size) had been tested. Either column gave

Fig. 2. The mass spectra of 6BT and the internal standard. The experimental conditions were the same as those described in Section 2.2.

Fig. 3. The proposed major fragments of 6BT and the internal standard.

Fig. 4. Representative MRM chromatograms of analytes in human plasma. (A) Double-blank plasma (no 6BT detected); (B) 3.00 ng/mL 6BT in plasma (at LLOQ with a S/N of 18.3); (C) 100 ng/mL 6BT in plasma; (D) double-blank plasma (no IS detected); and (E) 50.0 ng/mL IS in plasma.

reasonable retention time, symmetrical peaks, and sufficient resolution for 6BT and 2A6BT. However, YMC ODS-AQ column was chosen for the method development because it produced higher signal response than that of Gemini column.

Because 6BT and the IS are basic compounds, addition of formic acid (0.1%) in the mobile phase could not only protonate the analytes to enhance the sensitivity of MS detection, but also increase the hydrophilicity of the analytes to reduce the retention times of the analytes on the analytical column.

In this work, the percent content of acetonitrile in the mobile phase had also been optimized in terms of separation efficiency. A complete baseline resolution of 6BT and 2A6BT was achieved with a total run time of 7.0 using a mobile phase containing 35.0% of acetonitrile, 0.1% of formic acid and 64.9% of deionized water (v/v/v). To shorten the total run to 5.0 min, the percent content of acetonitrile in the mobile phase was increased to 45.0%, which resulted in the elution times of 2A6BT and 6BT at 3.5 and 3.9 min, respectively (Fig. 4). Although only a partial separation of between 6BT and 2A6BT was realized using 45.0% of acetonitrile in the mobile phase, these two compounds were completely separated from the sample matrix and quantified by MRM at different m/z . Therefore, a mobile phase containing 45.0% of acetonitrile, 0.1% of formic acid and 54.9% of deionized water (v/v/v) was adopted in the analytical procedure of the method, which not only improved the separation efficiency by nearly 30% but also showed no interference in 6BT quantification.

Table 1

Matrix effect and recovery.

Plasma matrices	[6BT] (ng/mL)	Recovery $\pm$ SD (%)	MF _{IS} $\pm$ SD
Mouse	9.00	82 $\pm$ 2	1.13 $\pm$ 0.06
	90.0	83 $\pm$ 1	1.10 $\pm$ 0.05
	900	87 $\pm$ 1	1.11 $\pm$ 0.04
Human	9.00	98 $\pm$ 5	0.97 $\pm$ 0.02
	90.0	90 $\pm$ 6	1.04 $\pm$ 0.02
	900	96 $\pm$ 7	1.04 $\pm$ 0.04

Each datum point was based on triplicate measurements.

Method validation

Method developed was validated by following the FDA guidelines for industry bioanalytical method validation [13].

Matrix effect and recovery

In this work, triplicate measurements were carried out at each concentration level for matrix effect and recovery studies. The effect (either suppression or enhancement) of sample matrix on analytical signal of 6BT was assessed by the IS normalized matrix factor (MF_{IS}) [14].

$$MF_{IS} = \frac{(A_{6BT}/A_{IS})_{matrix}}{(A_{6BT}/A_{IS})_{solvent}} \quad (1)$$

where $(A_{6BT}/A_{IS})_{matrix}$ is the peak area ratio of 6BT to the IS in SAE plasma matrix standard; and $(A_{6BT}/A_{IS})_{solvent}$ is the peak area ratio of 6BT to the IS in corresponding aqueous standard. As seen in Table 1, the MF_{IS} in mouse and human plasma matrices ranged 1.10–1.13 and 0.97–1.04, respectively. The values of MF_{IS} were quite reproducible with standard deviation (SD) $\leq$ 0.06 and consistent over the concentration range with a deviation of -0.03 to $+0.13$ from its ideal value of 1.00 (i.e., no matrix effect).

The IS normalized recoveries (R_{IS}) of 6BT from plasma samples were calculated by the following equation.

$$R_{IS} = \frac{(A_{6BT}/A_{IS})_{plasma}}{(A_{6BT}/A_{IS})_{matrix}} \times 100\% \quad (2)$$

where $(A_{6BT}/A_{IS})_{plasma}$ was the peak area ratio of 6BT to the IS in a plasma calibrator; and $(A_{6BT}/A_{IS})_{matrix}$ was the peak area ratio of 6BT to IS in the corresponding SAE standard. The recovery data were summarized in Table 1, which had values of 82–87% from mouse plasma and 90–98% from human plasma.

The absolute recoveries (R) of the IS from plasma samples were calculated by the following equation.

$$R = \frac{(A_{IS})_{plasma}}{(A_{IS})_{matrix}} \times 100\% \quad (3)$$

where $(A_{IS})_{plasma}$ and $(A_{IS})_{matrix}$ were the peak areas of the IS in a plasma calibrator and the corresponding SAE standard. The values of R ranged 59–66% and 60–64% in mouse and human plasma, respectively. Although the absolute recovery of the IS was not high, it was consistent within the calibration range.

Calibration curve, accuracy, and precision

6BT calibration curves in both mouse and human plasma were constructed using six non-zero plasma calibrators, one single-blank plasma (with IS only), and one double-blank plasma (with neither 6BT nor IS). The concentrations of 6BT in the non-zero samples were 3.00, 10.0, 30.0, 100, 300 and 1000 ng/mL. The linear calibration ranges (3.00–1000 ng/mL) were established in mouse and human plasma by plotting the peak area ratios of 6BT to the IS (A_{6BT}/A_{IS}) versus the concentrations of 6BT using $1/x$ (the reciprocal of 6BT concentration) weighted linear regression, and the calibration equations were given in Table 2. In this work, the lower limits

Table 2
Calibration equations of 6BT in mouse and human plasma.

Plasma matrices	Actual [6BT]	Measured [6BT]	SD	Accuracy (%)	Precision (%)
Mouse	3.00	2.84	0.04	5	1
	10.0	9.8	0.2	2	2
	30.0	30.3	0.9	-1	3
	100	101	4	-1	4
	300	301	9	-0.3	3
	1.00×10^3	1.00×10^3	0.01×10^3	0.2	1
Human	3.00	2.78	0.09	7	3
	10.0	9.8	0.3	2	3
	30.0	29.3	0.7	2	3
	100	102	1	-1	1
	300	3.1×10^2	0.2×10^2	-4	7
	1.00×10^3	9.9×10^2	0.2×10^2	1	2

Calibration equations: Mouse plasma, $Y = 0.020 (\pm 0.002)X - 0.007 (\pm 0.002)$, $R^2 = 1.00 (\pm 0.00)$. Human plasma, $Y = 0.017 (\pm 0.002)X - 0.003 (\pm 0.001)$, $R^2 = 0.999 (\pm 0.002)$. Each datum point was based on three separate measurements in different days.

Table 3
Accuracy, intra- and inter-assay precisions of 6BT in mouse and human plasma.

Mouse	LLOQ	LQC	MQC	HQC	DQC
Accuracy (%), $n = 5$	1	4	-3	3	5
Intra-assay precision, CV (%), $n = 5$	4	6	4	4	4
Inter-assay precision, CV (%), $n = 3$	4	5	5	3	4
Human	LLOQ/LQC	MQC	HQC		
Accuracy (%), $n = 5$	-13	-0.6	4		
Intra-assay precision, CV (%), $n = 5$	3	4	2		
Inter-assay precision, CV (%), $n = 3$	11	2	1		

The concentrations of 6BT in the LLOQ, LQC, MQC, HQC and DQC of mouse plasma were 3.00, 9.00, 90.0, 900 and 1.60×10^3 ng/mL, respectively. For the human plasma study, LQC, MQC, and HQC were 3.00, 90.0 and 900 ng/mL, respectively. The concentration of the IS was 50.0 ng/mL.

of quantification (LLOQ) were defined by lowest plasma calibrators of the calibration curves.

With the calibration equation, 6BT concentrations of the non-zero calibrators were obtained, and the accuracy as percent error was calculated. The precision as percent standard deviation or coefficient of variation (CV) was determined by replicate measurements. The results were summarized in Table 2, where accuracy ranged 0.2–5% and 1–7% and precision was 1–4% and 1–7% in mouse and human plasma, respectively. These values were well within the FDA guidelines (*i.e.*, $\leq \pm 15\%$ at all concentrations except at LLOQ where $\leq \pm 20\%$).

Table 4
Stability data of 6BT under various test conditions.

Storage conditions	Plasma matrices	[6BT] added (ng/mL)	Recovery $\pm$ SD (%)
Room temperature, 4 h	Mouse	9.00	88 $\pm$ 5
		900	94 $\pm$ 2
	Human	9.00	102 $\pm$ 7
		900	102 $\pm$ 2
Room temperature, 8 h	Mouse	9.00	68 $\pm$ 7
		900	87 $\pm$ 3
	Human	9.00	102 $\pm$ 8
		900	99 $\pm$ 1
Room temperature, 24 h	Mouse	9.00	19 $\pm$ 2
		900	30 $\pm$ 2
	Human	9.00	100 $\pm$ 4
		900	97 $\pm$ 1
Freeze-thaw (three cycles, -20°C)	Mouse	9.00	106 $\pm$ 10
		900	98 $\pm$ 8
	Human	9.00	100 $\pm$ 4
		900	103 $\pm$ 4
Long-term (30 days, -20°C)	Mouse	9.00	108 $\pm$ 7
		900	105 $\pm$ 1
	Human	9.00	108 $\pm$ 8
		900	108 $\pm$ 3

Each datum point was based on triplicate measurements.

The intra- and inter-assay precisions were further determined using five replicates of plasma control samples at low-, mid- and high-concentration levels (LQC, MQC and HQC). Since the LQC was different from LLOQ in mouse plasma study and one sampling point in mouse pharmacokinetic study exceeded the upper limit of quantification (ULOQ), the accuracy and precision of LLOQ and dilution quality control (DQC) for mouse plasma study were also included. The intra-assay precision was by the percent peak area ratios of 6BT to the IS of the five-replicate QC samples at each concentration level and the inter-assay precision was determined as by the percent peak area ratios of 6BT to the IS by triplicate measurements of

Fig. 5. Representative MRM chromatograms of mouse plasma samples. (A) pre-dosed mouse plasma with IS, (B) the plasma sample collected 5 min after intraperitoneal injection with IS, and (C) the plasma sample collected 13 min after intraperitoneal injection with IS.

a single QC sample at each concentration level, which ranged 3–6% and 0.6–11% in mouse and human plasma, respectively (Table 3). The accuracies of the above studies were –13 to 5% (Table 3), which were well within the FDA guidelines.

Stability

The stabilities of 6BT in mouse and human plasma were tested at two concentration levels (9.00 and 900 ng/mL) with triplicate measurements, and the results expressed as recovery were summarized in Table 4. As seen in Table 4, there was no significant loss of 6BT observed in human plasma under the tested conditions with recovery of 97–108%. For 6BT mouse plasma samples, they were stable at room temperature up to 4 h and after three freeze (–20 °C) and thaw (room temperature) cycles with recovery of 88–106%. Therefore, 6BT stock solutions and plasma samples were kept at –20 °C for this work, and the analysis of mouse plasma samples was done within 4-h timeframe.

Method application

The validated LC–MS/MS method was applied to a preliminary pharmacokinetic study of 6BT in mice. Mouse plasma samples collected by the procedure described in Section 2.7 were thawed in room temperature. The mouse plasma samples together with eight calibrators (*i.e.*, one single-blank, one double-blank and six non-zero) and two sets of QC at low-, mid- and high-concentrations (*i.e.*, 9, 90, 900 ng/mL) were extracted after adding the IS solution and analyzed by the validated method. The sample having a concentra-

Fig. 6. Plasma concentration–time profile of 6BT in male C57BL/6 mice after intraperitoneal injection at dosage of 1 mg 6BT/kg mouse.

tion beyond the ULOQ (*i.e.*, 1000 ng/mL) had been re-run along with the dilution QC (DQC) at the concentration of 1600 ng/mL after 1:1 dilution with blank mouse plasma.

Representative mass chromatograms of mouse plasma samples were shown in Fig. 5, where no sign of interference from endogenous compound in mouse plasma was observed. The 6BT concentration in mouse plasma after single bolus injection was illustrated in Fig. 6, which fitted well in a nonlinear one-compartment first-order pharmacokinetic model that has the following estimated parameters with percent relative standard deviations of 12–15%: T_{max} , 18.9 min; C_{max} 1086 ng/mL; $T_{1/2}$ 13.1 min; and AUC, 55,731 min ng/mL.

Conclusions

An LC–MS/MS method for the quantitative determination of 6BT in mouse and human plasma has been developed and validated. Analytes in plasma were first extracted by ethyl acetate and then separated by Waters YMC ODS-AQ® column prior to the tandem mass spectrometric detection. Method validation has been carried out according the FDA guideline. This method had a linear calibration range of 3.00–1000 ng/mL for 6BT in both mouse and human plasma, and has been successfully applied to the pharmacokinetic study of 6BT in mice. It may be useful in therapeutic development of 6BT and its analogues in human.

References

- [1] B.M. Chassy, R.J. Suhadolnik, *J. Biol. Chem.* 242 (1967) 3655.
- [2] M.H. Iltzsch, S.S. Uber, K.O. Tankersley, M.H. el Kouni, *Biochem. Pharmacol.* 49 (1995) 1501.
- [3] M.H. el Kouni, V. Guarcello, O.N. Al Safarjalani, F.N. Naguib, *Antimicrob. Agents Chemother.* 43 (1999) 2437.
- [4] J.P. Dubey, C.P. Beattie, *Toxoplasmosis of Animals and Man*, CRC Press, Boca Raton, FL, 1988, p. 1.
- [5] P.D. Walzer, R.M. Genta (Eds.), *Parasitic Infections in the Compromised Host*, Marcel Dekker, New York, NY, 1989, p. 179.
- [6] D.N. Wald, H.M. Vermaat, S. Zang, A. Lavik, Z. Kang, G. Peleg, S.L. Gerson, K.D. Bunting, M.L. Agarwal, B.L. Roth, W. Tse, *Cancer Res.* 68 (2008) 4369.
- [7] American Society of Clinical Oncology, *Leukemia—Acute Myeloid: Overview*, 2009, available at <http://www.cancer.net/patient/Cancer+Types/Leukemia+-+Acute+Myeloid+-+AML>.
- [8] E. Estey, H. Döhner, *Lancet* 368 (2006) 1894.
- [9] B. Steffen, C. Müller-Tidow, J. Schwäble, W.E. Berdel, H. Serve, *Crit. Rev. Oncol. Hematol.* 56 (2005) 195.
- [10] Z.Y. Wang, Z. Chen, *Blood* 111 (2008) 2505.
- [11] M.S. Tallmann, *Ann. Hematol.* 83 (2004) S81.
- [12] R.H. Rais, O.N. Al Safarjalani, V. Yadav, V. Guarcello, M. Kirk, C.K. Chu, F.N. Naguib, M.H. el Kouni, *Biochem. Pharmacol.* 69 (2005) 1409.
- [13] U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), *Guidance for Industry: Bioanalytical Method Validation*, 2001, available at <http://www.fda.gov/cder/guidance/4252fnl.htm>.
- [14] E.R. Badman, Z. Liang, S. Bansal, J. Gibbons, *Applied Biosystems Users Meeting*, ASMS, Denver, CO, June 1, 2008.